EAACI Viena 2016

This symposium, which covers bilastinethe development of medicinal products for paediatric use and safety is sponsored FAES FARMA.

It is sometimes thought that drug development is somewhat distant from clinical needs. With regard to the paediatric population, many physicians consider that it is essential to have a safe and effective drug.

This symposium presents some interesting findings concerning the safety and efficacy of bilastine in paediatric use. Both these factors are included in the obligatory Paediatric Study Plan for all new drugs under development in Europe.

Only registered health professionals are allowed to see the report